ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / MGTX / dividends
GLUE (25) ODTX (46) CGEM (32) PRME (30) ⌘ Pro Terminal →

MeiraGTx Holdings plc (MGTX) Dividend Safety Gauge & 10-Year DRIP Compounder

$9.32 -1.79% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.27

MeiraGTx Holdings plc (MGTX) carries a Roarable Rating of E (Strong Sell) with 20/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $911.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MGTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MGTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, MeiraGTx Holdings plc (NASDAQ: MGTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 20/100 at a spot price of $9.32 (-1.79% 1D, market cap $911.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, MGTX ranks #975 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MGTX compare to GLUE and ODTX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), MGTX carries a Roarable E (20/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GLUE (Monte Rosa Therapeutics Inc.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $918.0M) and ODTX (Odyssey Therapeutics Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $939.1M). Among the 5-stock peer group, MGTX leads on earnings multiple (N/A) while MGTX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MGTX?
▼

Per MGTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001735438), MeiraGTx Holdings plc generated $81.4M in revenue (+144.6% YoY), $0 in net income, and -$50.2M in free cash flow against $244.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $9.27 (-0.51%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (20/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510020
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk E
Cash (3)Whales (4)SEC (7)Macro (3)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-17.1% Base Target
$16 Bull$8 Base$6 Bear
📬 FREE MGTX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MGTX)Realized 20D OHLCV Swing Band: ±10.6%
Deterministic 5-Pillar Attribution (20/100 Composite)
🔍 WHY MGTX SCORES 20/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+7/20 pts (35% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Cash Engine Quality+4/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
28
Grade E$9.94+0.3% Next Q
Q2 (-2Q)
25
Grade E$9.97-5.7% Next Q
Q3 (-1Q)
23
Grade E$9.40-0.9% Next Q
Current
20
Grade E$9.32-11.8% Hist 90D α
Trajectory: E (28) → E (20)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MGTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MGTX currently carries a cautious 20/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.51) and Max Pain ($9.79) forces dealer call-delta covering toward $16.12.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MGTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MGTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 20%NO 80%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
0.6% Total Yield
0% Cash ($0.00/yr) + 0.6% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (15.1% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $40,809

Est. Year-10 Shareholder Yield: $245/yr
$11.5K
Yr 1
$13.2K
Yr 2
$15.2K
Yr 3
$17.6K
Yr 4
$20.2K
Yr 5
$23.3K
Yr 6
$26.8K
Yr 7
$30.8K
Yr 8
$35.5K
Yr 9
$40.8K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MGTX)

  • ✓Walkthrough of MGTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MGTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -3.92%🛡️ HOLDING TREND SUPPORT
2026-11-03O $9.70H $9.70L $9.32C $9.32VOL 452.2K
RES: $15.25SUP: $8.82SMA50: $11.51SMA200: $10.33
$15.86$13.76$11.67$9.57$7.48RES $15.25SUP $8.82$9.322026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MGTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MGTX Butterfly Map → + Track MGTX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +144.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MGTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MGTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MGTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MGTX)

Health Care Rank #975 of 1015 ⚔️ GLUE vs MGTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MGTX vs. GLUE, ODTX, CGEM, PRME)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, MeiraGTx Holdings plc (MGTX) ranks #975 by composite RQD confidence (20/100, grade E) and #368 by equity capitalization ($911.4M). Within this direct 5-issuer industry benchmark cohort, MGTX leads on earnings valuation at N/A trailing P/E, while MGTX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with MGTX at 20/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MGTX ACTIVE
MeiraGTx Holdings plc
E 20/100 — — -35.0% -1.79% $911.4M Benchmark Subject
GLUE
Monte Rosa Therapeutics Inc.
E 25/100 — — -35.0% -1.21% $918.0M /glue-vs-mgtx →
ODTX
Odyssey Therapeutics Inc.
D 46/100 — — — -0.05% $939.1M /odtx-vs-mgtx →
CGEM
Cullinan Therapeutics Inc.
E 32/100 — — -35.0% -0.66% $967.3M /cgem-vs-mgtx →
PRME
Prime Medicine Inc.
E 30/100 — — -35.0% -5.93% $856.1M /prme-vs-mgtx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001735438 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), MeiraGTx Holdings plc (MGTX) reported GAAP revenue of $81.4M (+144.6% vs. FY2024 revenue of $33.3M , and +480.7% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of -$46.4M, and free cash flow of -$50.2M (+54.1% YoY). On the balance sheet, MGTX closed FY2025 with $244.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $81.4M $0 -$46.4M -$50.2M $244.4M —
FY2024 (FY) 2024-12-31 $33.3M $0 -$104.5M -$109.5M $269.8M —
FY2023 (FY) 2023-12-31 $14.0M $0 -$105.4M -$105.4M — —

3. MGTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MGTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, MeiraGTx Holdings plc (NASDAQ: MGTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 20/100 at a spot price of $9.32 (-1.79% 1D, market cap $911.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, MGTX ranks #975 in composite RQD confidence.

How does MGTX compare to GLUE and ODTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), MGTX carries a Roarable E (20/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GLUE (Monte Rosa Therapeutics Inc.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $918.0M) and ODTX (Odyssey Therapeutics Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $939.1M). Among the 5-stock peer group, MGTX leads on earnings multiple (N/A) while MGTX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MGTX?

Per MGTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001735438), MeiraGTx Holdings plc generated $81.4M in revenue (+144.6% YoY), $0 in net income, and -$50.2M in free cash flow against $244.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MGTX trading relative to its 50-day, 200-day, and 52-week technical levels?

MGTX last traded at $9.32 (-1.79% on volume of 580,141 shares), positioning the stock -19.03% below its 50-day simple moving average ($11.51) and -9.78% below its 200-day simple moving average ($10.33). Across its 52-week range of $6.62 to $15.35, MGTX sits at the 30.9% percentile with a 14-day RSI of 39.5 (NEUTRAL RANGE) and an implied next-earnings move of ±10.6% ($8.33 to $10.31).

Direct Sub-Reports: MGTX RQD Cockpit MGTX 12M Forecast MGTX Earnings & Move MGTX Dividends & DRIP MGTX Insiders & 13F MGTX Whale Options MGTX Profit Sankey MGTX News & Why
ROARABLE RATING BRIEF • RQD 20/100 (E) ✓ SEC XBRL & RQD VERIFIED

MGTX — MeiraGTx Holdings plc: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

MeiraGTx Holdings plc (MGTX) earns a live Roarable RQD composite score of 20/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $9.32 (-1.79% 1D, market capitalization $911.4M).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -5.38%.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (3/20) + Forensic Balance Sheet (7/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Reported revenue is $81.4M for FY 2025, .

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), MeiraGTx Holdings plc (MGTX) reported $81.4M in annual revenue (up from $33.3M in FY2024, +144.6% YoY) and $0 in GAAP net income. Over the multi-year SEC filing window from FY2023 ($14.0M revenue, $0 net income) through FY2025, MGTX scaled operating cash flow to -$46.4M and free cash flow to -$50.2M, backed by $244.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 20/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -5.38% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $6.62 – $15.35 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), MGTX carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can MGTX sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $81.4M and free cash flow of -$50.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is MGTX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MGTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for MeiraGTx Holdings plc (MGTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MGTX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MGTX Bull vs. Bear Conversation Board — What's Your Call at $9.32?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MGTX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MGTX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $11.39 (+20.0%)
📌 Pinned Debate

Reported FY 2025 revenue grew to $81.4M from $33.3M in FY 2024, and cash of $65.9M remains on the balance sheet.

Long MGTX at $9.49 targeting $11.39. Reported FY 2025 revenue grew to $81.4M from $33.3M in FY 2024, and cash of $65.9M remains on the balance sheet.. Institutional whale score is 4/20 and the risk/reward vs. the $6.62 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

@MultipleCompression Shorting a 4/20 institutional whale-flow stock at $9.49 is dangerous when funds are rotating into Health Care.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $7.21 (-24.0%)
Spot @ $9.49

With an Altman Z of 0.2, a Piotroski F of 1/9, ROIC of -35%, and operating income of -$106.0M in FY 2025, the forensic and cash-generat

Here is the bear case nobody on the bull side wants to address on MGTX: With an Altman Z of 0.2, a Piotroski F of 1/9, ROIC of -35%, and operating income of -$106.0M in FY 2025, the forensic and cash-generation profile is weak.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Biological Products (No Diagnostic Substances) triggers a 12-15% air pocket.

LIVE TAPE